Oleg Bess, MD


Data Quality Issues Plague the US Health Care System

Oleg Bess, MD, explains why data quality is essential to improving the United States health care system.

Preetesh Jain, MD, PhD


Dr. Jain on Ongoing Research Efforts in MCL

Preetesh Jain, MD, PhD, discusses ongoing research efforts in mantle cell lymphoma.

Deborah B. Doroshow, MD, PhD


Dr. Doroshow on the Impact of the COVID-19 Pandemic on Cancer Care

Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.

Eva M. Ciruelos Gil, MD, PhD


Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast Cancer

Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.

Sikander Ailawadhi, MD


Treatment Options in Early Relapse Multiple Myeloma

Dr Joseph Mikhael and expert panel review current treatment options for patients with early relapse multiple myeloma, in accordance with current NCCN guidelines.

Nilay Shah, MD


Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid Tumors

Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.

Steven Waguespack, MD


Long-Term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-Positive Thyroid Carcinoma

Dr. Waguespack reviews efficacy and safety data for larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

Stephan L. Chan, MD, The Chinese University of Hong Kong


Future Directions for HCC Management

Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.

Shumei Kato, MD


Dr. Kato on the Characterization of BRAF Mutations in Oncology

Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.

Madan L. Arora, MD


Dr. Arora on the Evolution of Treatment in Follicular Lymphoma

Madan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.

Evan J. Lipson, MD, Johns Hopkins Medicine


Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLC

Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).

Georges Azzi, MD


Dr. Azzi on the Utilization of the Signatera ctDNA Assay in the CIRCULATE-US Trial in CRC

Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.



Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial Carcinoma

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.

Usman Ali Akbar, MD


Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALL

Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Chan Cheah, MBBS


Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLL

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.

Ashley Ross, MD, PhD, Northwestern Medicine


Operational Processes and Challenges

Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.

Jason Brayer, MD, PhD


Dr. Brayer on the Promise of BiTEs in Multiple Myeloma

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

Anant Ramaswamy, MD


Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.

Kevin Zarrabi, MD


Dr. Zarrabi on the Real-World Data With Axitinib/Pembrolizumab Vs Ipilimumab/Nivolumab in Clear Cell RCC

Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.

Susan Faye Dent, MD


Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

Susan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.

Martine Extermann, MD, PhD


Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast Cancer

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University


Advanced Biliary Tract Cancers: Novel Biomarker Strategies

Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.

John L. Hays, MD, PhD


Dr. Hays on the Importance of Clinical Trials in CRC

John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.

Wesley J. Talcott, MD, MBA


Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

Lakshmi Rajdev, MD, MS


Dr. Rajdev on Detecting HER2 Positivity in GI Cancer

Lakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.

Nikhil Wagle, MD


Direct Partnership With Patients May Accelerate Cancer Research and Precision Oncology

During the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.

Brian Ramnaraign, MD


Dr. Ramnaraign on the Evaluation of Atezolizumab Plus Tivozanib in GI Malignancies

Brian Ramnaraign, MD, discusses the evaluation of atezolizumab plus tivozanib in a phase 1b/2 trial in patients with pancreatic, gallbladder, and bile duct cancers.

Kim E. Nichols, MD


Dr. Nichols on the Prognosis of Patients With VHL Disease

Kim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.